Arjan W. Griffioen, Judy R. van Beijnum, Sacha Jacobs, Mattie Cassee, Myra Castel, Patrycja Nowak-Sliwinska
{"title":"The vascular contribution to immunotherapy success","authors":"Arjan W. Griffioen, Judy R. van Beijnum, Sacha Jacobs, Mattie Cassee, Myra Castel, Patrycja Nowak-Sliwinska","doi":"10.1007/s10456-026-10036-w","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Angiogenesis represents a mechanism enabling tumors to evade immune surveillance. This immune escape is mediated, at least in part, by angiogenic factor-induced endothelial cell anergy, which suppresses leukocyte adhesion and infiltration into the tumor microenvironment. Consequently, it is becoming increasingly evident that the efficacy of immunotherapy can be improved by its combination with anti-angiogenic agents. Numerous studies, including clinical trials, have provided proof of this concept. A paper in this issue of <i>Angiogenesis</i> further substantiates this paradigm by demonstrating that normalizing the tumor vasculature and overcoming endothelial cell anergy also ameliorates the activity of CAR T cell therapy. Here, we place these findings into a broader mechanistic context and discuss their implications for combination treatment strategies.</p>\n </div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"29 2","pages":""},"PeriodicalIF":11.2000,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiogenesis","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s10456-026-10036-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Angiogenesis represents a mechanism enabling tumors to evade immune surveillance. This immune escape is mediated, at least in part, by angiogenic factor-induced endothelial cell anergy, which suppresses leukocyte adhesion and infiltration into the tumor microenvironment. Consequently, it is becoming increasingly evident that the efficacy of immunotherapy can be improved by its combination with anti-angiogenic agents. Numerous studies, including clinical trials, have provided proof of this concept. A paper in this issue of Angiogenesis further substantiates this paradigm by demonstrating that normalizing the tumor vasculature and overcoming endothelial cell anergy also ameliorates the activity of CAR T cell therapy. Here, we place these findings into a broader mechanistic context and discuss their implications for combination treatment strategies.
期刊介绍：
Angiogenesis, a renowned international journal, seeks to publish high-quality original articles and reviews on the cellular and molecular mechanisms governing angiogenesis in both normal and pathological conditions. By serving as a primary platform for swift communication within the field of angiogenesis research, this multidisciplinary journal showcases pioneering experimental studies utilizing molecular techniques, in vitro methods, animal models, and clinical investigations into angiogenic diseases. Furthermore, Angiogenesis sheds light on cutting-edge therapeutic strategies for promoting or inhibiting angiogenesis, while also highlighting fresh markers and techniques for disease diagnosis and prognosis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
